Evidence map›Paper›PMID 42255251›Full record

ArticleFrontiers in oncology2026

Venous thromboembolism and secondary outcomes of bleeding and mortality in patients with gliomas: a multicenter cohort study.

Viviane Cordeiro Veiga, Camilla Akemi Felizardo Yamada, Carlos Afonso Clara, Jessica Carolina Andrade Dos Santos, Breno Gray Milano, Danielli de Almeida Matias, Pedro Hortêncio Saboia da Escossia Melo, Gabriel N de Rezende Batistella, Alexandre Biasi Cavalcanti, Fabiana Spillari Viola and 13 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Viviane Cordeiro VeigaBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Camilla Akemi Felizardo YamadaBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Carlos Afonso ClaraHospital de Amor - Fundação Pio XII, Barretos, São Paulo, Brazil.
Jessica Carolina Andrade Dos SantosHospital de Amor - Fundação Pio XII, Barretos, São Paulo, Brazil.
Breno Gray MilanoICESP - Instituto do Câncer de São Paulo, São Paulo, Brazil.
Danielli de Almeida MatiasDepartment of Oncology, Liga Norte Riograndense Contra o Câncer, Natal, Brazil.
Pedro Hortêncio Saboia da Escossia MeloInstitute of Education, Research, and Innovation, Liga Norte Riograndense Contra o Câncer, Natal, Brazil.
Gabriel N de Rezende BatistellaHcor Research Institute, São Paulo, Brazil.
Alexandre Biasi CavalcantiHcor Research Institute, São Paulo, Brazil.
Fabiana Spillari ViolaHospital São Lucas da Pontifícia Universidade Católica, Rio Grande do Sul, Brazil.
Ana Carolina LevyAC Camargo Cancer Center, São Paulo, Brazil.
Silvana Soares Dos SantosAC Camargo Cancer Center, São Paulo, Brazil.
Carolina FittipaldiINCA - Instituto Nacional do Câncer, Rio de Janeiro, Brazil.
Mauro Bráulio da Rosa PintoINCA - Instituto Nacional do Câncer, Rio de Janeiro, Brazil.
Daniela Galvão Barros de OliveiraHospital Santa Izabel - Santa Casa da Bahia, Salvador, Bahia, Brazil.
Thiago Santos VieiraHospital Santa Izabel - Santa Casa da Bahia, Salvador, Bahia, Brazil.
Flavia Regina de MoraesBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Thatiane Lopes Valentim Di Paschoaele OstolinBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Talita Rantin BelucciBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Feres Chaddad-NetoDepartment of Neurosurgery, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Alex Machado BaetaBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Iuri Santana NevilleBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
Stela Verzinhasse PeresBP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Venous thromboembolism (VTE) is a common and clinically significant complication in Central Nervous system (CNS) tumors, associated with increased hospitalization, morbidity, and mortality. This study estimates the cumulative incidence of VTE, bleeding, and all-cause mortality in patients with primary gliomas and evaluates their determinants using multivariable models accounting for competing risks, confounding, and missing data. Methods: This multicenter retrospective cohort study evaluated 334 adults with histologically confirmed primary gliomas treated across nine Brazilian centers (2021-2022; follow-up to December 2023). Outcomes included VTE, bleeding, and all-cause mortality. Sociodemographic, clinical, tumor-specific, treatment, and thromboprophylaxis data were collected. Twelve-month cumulative incidence was estimated using competing-risk methods. VTE and bleeding were assessed with Fine-Gray sub distribution hazard models, and mortality with Cox proportional hazards models. Results: VTE and bleeding cumulative incidences at 12 months were 11.8% (8.0 - 15.5% CI) and 4.7% (2.1 - 7.3% CI). The cumulative mortality incidence was 26.2%. Prior VTE (SHRadj = 4.28; 95% CI 2.60 - 7.07) and corticosteroid use (SHRadj = 3.25; 95% CI 2.20 - 4.81) independently increased VTE risk. Chronic kidney failure (SHRadj = 6.45; 95% CI 5.39 - 7.73) and diabetes mellitus SHRadj = 2.11; 95% CI: 1.51 - 2.95) were the independent predictor of bleeding. For mortality, gliomas NOS (HRadj = 9.20; 95% CI: 5.38-15.73) and GBM (HRadj = 10.34; 95% CI 4.28 - 24.96) were strongly associated with increased risk. Longer hospitalization (≥7 days; HRadj = 2.01; 95% CI 1.81 - 2.24), postoperative bleeding (HRadj = 2.92; 95% CI 2.10 - 4.13), and treatment in specialized cancer centers (HRadj = 2.59; 95% CI: 1.50 - 4.50), along with demographic characteristics, were also associated with higher mortality. Conclusion: In this multicenter Brazilian cohort of patients with primary gliomas, VTE was frequent, while bleeding was less common but clinically relevant. Mortality risk was driven by patient characteristics, tumor aggressiveness, and hospitalization factors, underscoring the need for individualized risk stratification. Within the subgroup analysis for mortality, higher educational level was associated with lower hazard of death, whereas prolonged hospitalization and postoperative bleeding consistently increased mortality risk across both GBM and grade 3 or 4 tumors.

Indexed as

central nervous system neoplasmsneoplasm complicationsprognostic factorsupper-middle income countriesvenous thromboembolism

Identifiers

PMID42255251
PMCPMC13233262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.